# OnCo record car-t (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/car-t/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "car-t" ;
  schema:name "CAR-T cell therapy"@en ;
  schema:alternateName "CAR-T"@en, "CAR T cells"@en, "CAR T-cell therapy"@en, "Chimeric antigen receptor T cells"@en ;
  schema:description "A patient's T cells are removed, given a synthetic receptor that recognises the cancer, multiplied, and put back as a living drug."@en ;
  schema:url <https://onco.cc/technologies/car-t/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell> ;
  schema:citation <https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell>, <https://doi.org/10.1073/pnas.86.24.10024>, <https://doi.org/10.1158/2159-8290.CD-15-1020>, <https://doi.org/10.1038/s41591-020-1061-7> ;
  onco:status "approved" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/in-vivo-car-t/>, <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/armored-car/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/cldn18-2/>, <https://onco.cc/targets/gpc3/>, <https://onco.cc/targets/gprc5d/>, <https://onco.cc/targets/cd70/>, <https://onco.cc/targets/mesothelin/> ;
  onco:drugs <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/satricabtagene-autoleucel/> ;
  onco:companies <https://onco.cc/companies/cellogen/>, <https://onco.cc/companies/adicet-bio/>, <https://onco.cc/companies/allotera-therapeutics/>, <https://onco.cc/companies/arcellx/>, <https://onco.cc/companies/cargo-therapeutics/>, <https://onco.cc/companies/century-therapeutics/>, <https://onco.cc/companies/imugene/>, <https://onco.cc/companies/leah-labs/>, <https://onco.cc/companies/lyell-immunopharma/>, <https://onco.cc/companies/modulari-t/>, <https://onco.cc/companies/poseida-therapeutics/>, <https://onco.cc/companies/tmunity-therapeutics/>, <https://onco.cc/companies/cartesian-therapeutics/>, <https://onco.cc/companies/vor-biopharma/>, <https://onco.cc/companies/cartx-therapeutics/>, <https://onco.cc/companies/juventas-cell-therapy/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/lymphoma-bio-antigen-escape/>, <https://onco.cc/terms/lymphoma-bio-lineage-antigen-cost/> ;
  onco:trials <https://onco.cc/trials/nct07036250/>, <https://onco.cc/trials/nct05759728/>, <https://onco.cc/trials/nct07103668/> ;
  onco:people <https://onco.cc/people/zelig-eshhar/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gross-eshhar-chimeric-receptor-pnas-1989/> ;
  onco:dependsOn <https://onco.cc/technologies/apheresis-starting-material/>, <https://onco.cc/technologies/viral-vector-manufacturing/>, <https://onco.cc/technologies/cell-therapy-cold-chain/>, <https://onco.cc/technologies/cell-therapy-release-testing/>, <https://onco.cc/technologies/cell-therapy-orchestration-software/> .